Real‐world treatment outcomes of neovascular Age‐related Macular Degeneration in the Netherlands-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Real‐world treatment outcomes of neovascular Age‐related Macular Degeneration in the Netherlands

Published:2020-12-23 Issue:6 Volume:99 Page:
ISSN:1755-375X
Container-title:Acta Ophthalmologica
language:en
Short-container-title:Acta Ophthalmol

Author:

Verbraak Frank D.¹^ORCID,Ponsioen Dirk L.²,Tigchelaar‐Besling Odette A.M.³,Nguyen Vuong⁴,Gillies Mark C.⁴,Barthelmes Daniel⁵,Klaver Caroline C.W.⁶⁷

Affiliation:

1. Department of Ophthalmology Amsterdam University Medical Center Amsterdam The Netherlands

2. Department of Ophthalmology Isala Clinic Zwolle The Netherlands

3. Department of Ophthalmology Amphia Clinic Breda The Netherlands

4. The Save Sight Institute Sydney Medical School University of Sydney Sydney NSW Australia

5. Department of Ophthalmology Zurich University Medical Clinic Zurich Switzerland

6. Department of Ophthalmology Radboud University Medical Clinic Nijmegen The Netherlands

7. Department of Ophthalmology Erasmus Medical Center Rotterdam The Netherlands

Publisher

Wiley

Subject

Ophthalmology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/aos.14712

Reference23 articles.

1. Effects of switching from ranibizumab to aflibercept in eyes with exudative age-related macular degeneration

2. A pharmacoepidemiologic study of ranibizumab and aflibercept use 2013–2016. The Fight Retinal Blindness! Project

3. Ranibizumab or Bevacizumab for Neovascular Age-Related Macular Degeneration According to the Lucentis Compared to Avastin Study Treat-and-Extend Protocol

4. Comparison of Ranibizumab and Bevacizumab for Neovascular Age-Related Macular Degeneration According to LUCAS Treat-and-Extend Protocol

5. Treatment Outcomes of Ranibizumab versus Aflibercept for Neovascular Age-Related Macular Degeneration

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comparison of Methods of Clinical Trial Emulation Utilizing Data From the Comparison of AMD Treatment Trial (CATT) and the IRIS® Registry;Ophthalmology Science;2024-09

2. Perspectives of Patients and Professionals on Implementing a Computer Adaptive Vision-Related Quality of Life Outcome (CAT-EyeQ) in Clinical Practice;Translational Vision Science & Technology;2024-03-12

3. Management of Neovascular Age-Related Macular Degeneration Treatment in France from 2008–2018: The Nationwide LANDSCAPE Study;Ophthalmology and Therapy;2023-08-02

4. The ideal intravitreal injection setting: office, ambulatory surgery room or operating theatre? A narrative review and international survey;Graefe's Archive for Clinical and Experimental Ophthalmology;2023-05-18

5. Visual impairment due to age‐related macular degeneration during 40 years in Finland and the impact of novel therapies;Acta Ophthalmologica;2022-08

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3